| T | Act | Project | Year | Sub | Principal Investigator(s)/ Project Leader(s) | Organization | Fiscal Year | Admin IC | Funding IC | FY Total Cost by IC | Similar Projects |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CVL-354, a kappa opioid receptor antagonist for treatment of opioid use disorder, withdrawal and relapse | |||||||||||
| 5Tf | UH3Actf | DA052166Projectf | 03Yearf | CEREVEL THERAPEUTICS, LLC | 2024 | NIDA | NIDA | $2,700,000 | View View Similar Projects Similar Projectsf | ||
| CVL-354, a kappa opioid receptor antagonist for treatment of opioid use disorder, withdrawal and relapse | |||||||||||
| 4Tf | UH3Actf | DA052166Projectf | 02Yearf | CEREVEL THERAPEUTICS, LLC | 2023 | NIDA | NIDA | $2,700,000 | View View Similar Projects Similar Projectsf | ||
| T | Act | Project | Year | Sub | Principal Investigator(s)/ Project Leader(s) | Organization | Fiscal Year | Admin IC | Funding IC | FY Total Cost by IC | Similar Projects |
|---|